Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiomyopathy
Pharma
AstraZeneca, Ionis shares slide with ATTR-CM trial failure
The failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in ATTR-CM has sent their shares tumbling, while competitors are soaring.
Kevin Dunleavy
Jul 9, 2026 11:36am
Cytokinetics scores with Myqorzo in key cardiomyopathy trial
May 5, 2026 8:00am
BridgeBio CEO shrugs off recent Attruby pricing pressure fears
Feb 25, 2026 2:30pm
Trial win for BMS sets up Camzyos for pediatric expansion
Jan 12, 2026 10:25am
Cytokinetics scores its first FDA nod with Myqorzo approval
Dec 22, 2025 12:05pm
Is Pfizer's recent ATTR sales decline in the US a warning sign?
Dec 2, 2025 8:20am
